Adicet Bio, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Adicet is a clinical-stage biotechnology company developing allogeneic gamma delta T-cell therapies. It has no products approved for sale and generated no product revenue.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | No revenue; no Regeneron revenue recorded in the quarter | No revenue reported for the comparable quarter |
| Research and development expense | $23.9 million | $26.8 million |
| General and administrative expense | $7.0 million | $6.6 million |
| Total operating expenses | $30.9 million | $33.3 million |
| Net loss | $28.0 million | $30.9 million |
| Basic and diluted loss per share | $0.35 | $0.72 |
| Net cash used in operating activities | $22.8 million | $24.1 million |
| Cash and cash equivalents | $247.6 million at March 31, 2024 | $159.7 million at December 31, 2023 |
| Total liabilities | $34.3 million | $37.1 million at December 31, 2023 |
Interest income was $2.9 million, up from $2.7 million, primarily reflecting higher interest rates and Treasury investments. No income tax expense was recorded. Gross margin is not applicable because the company reported no revenue.
Material changes and financing
- Operating expenses declined 7% year over year. R&D fell 11%, mainly from a $3.1 million decrease in CDMO and other externally conducted R&D costs; G&A rose 6%, mainly due to higher stock-based compensation and salaries.
- Net loss narrowed by $2.9 million year over year. Operating cash use was $1.2 million lower than in Q1 2023.
- Q1 financing provided $111.0 million net: approximately $91.7 million from a public offering and $19.3 million from the ATM program. The offering included common shares and 8.45 million pre-funded warrants, each exercisable for a share at $0.0001.
- Common shares outstanding increased from 43.27 million at year-end 2023 to 82.17 million at March 31, 2024. The filing identifies the offering as significantly dilutive.
- The JonesTrading ATM program was terminated effective March 15, 2024. Adicet entered a new Jefferies ATM agreement in March; no shares had been sold under it as of March 31.
Liquidity, debt and outlook
Adicet had no indebtedness outstanding under its Banc of California loan agreement at March 31, 2024 and reported covenant compliance. The term-loan facility expired in April 2024; ancillary treasury services of up to $5.5 million remained available. Operating lease liabilities totaled $20.0 million, including $3.3 million current.
Management said cash and cash equivalents were expected to fund forecast operating expenses, capital expenditures and debt service for at least 12 months from issuance of the interim financial statements. Separately, the risk factors state the company believed its March 31 cash position capitalized it into the second half of 2026, while warning that additional funding will be needed beyond that point and that actual cash use could be faster than forecast. The filing does not provide a single reconciled runway estimate.
Management expects continued significant losses and negative operating cash flows, with no significant product revenue expected until a candidate is approved and commercialized or additional collaborations are entered into. It anticipates needing substantial additional capital; financing may not be available on acceptable terms or at all.
Programs, guidance and key risks
- ADI-001, autoimmune disease: FDA-cleared IND for lupus nephritis in December 2023. The company expected to initiate a Phase 1 trial in Q2 2024 and pursue one or two additional autoimmune indications in Q2–Q3 2024, subject to IND clearance. Preliminary lupus nephritis data were anticipated in Q4 2024 or Q1 2025, subject to site activation and enrollment.
- ADI-001, NHL: The company deprioritized enrollment of large B-cell lymphoma patients to focus on mantle cell lymphoma. It expected an NHL clinical update, including additional MCL safety and efficacy data, in the second half of 2024. A potential pivotal Phase 2 regulatory path was to be defined in the first half of 2025, subject to data and regulatory feedback.
- ADI-270: Preclinical candidate targeting CD70-positive cancers, with renal cell carcinoma as the initial indication. The company planned to file an IND in Q2 2024 and anticipated clinical data in the first half of 2025, subject to regulatory clearance and study initiation.
- Major risks include clinical safety, efficacy and enrollment uncertainty; novel-platform and manufacturing challenges; reliance on third-party suppliers and trial operators; competition; intellectual-property risks; and the need for further financing. The company also highlighted possible supply-chain effects from geopolitical conflicts and the limited number of authorized common shares available for future issuance.
- At the 2024 annual meeting, the company sought approval to increase authorized common shares from 150 million to 300 million. Failure to obtain approval could constrain financing, strategic transactions and equity compensation.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter. No material legal proceedings were disclosed.
Investor verification points
- Check subsequent filings for actual ADI-001 and ADI-270 trial starts, enrollment, safety findings and timing or content of clinical updates.
- Reconcile the stated 12-month liquidity expectation with the separate “into the second half of 2026” runway statement, and monitor cash burn and any revised financing needs.
- Verify the outcome of the authorized-share increase proposal and assess the potential dilution from shares, warrants, equity awards and any future ATM sales.
- Monitor manufacturing capacity and third-party supply performance, given their importance to clinical timelines and product availability.
- Track whether the expired term-loan facility or remaining ancillary services create any new financing, covenant or liquidity obligations.